Home/Capabilities/Regulatory excellence/Raw material compliance
Regulatory excellence
Raw material compliance
The quality of the finished product depends on the quality of the materials used to make it — and inspectors increasingly assess whether you understand that risk, not just whether the material met its specification.
Why it matters
Quality is built in from the first ingredient, not tested in at release
Manufacturers focus on process validation, analytical testing and finished product release. Regulators keep returning to a simpler point: the quality of the finished product depends on the quality of the materials used to make it.
Raw material qualification is the systematic demonstration that a material, its supplier and its manufacturing process consistently meet defined quality, safety and regulatory requirements — before the material is approved for use. It is not a procurement activity. It is a cornerstone of the pharmaceutical quality system.
The industry has learned this repeatedly and expensively. The heparin contamination event, in which oversulfated chondroitin sulfate was substituted for genuine material, caused acute reactions in patients across multiple countries. Nitrosamine impurities in widely used APIs triggered one of the largest recall programmes in pharmaceutical history. Both trace to quality risk that originated at the start of the supply chain, not at finished-product release.
By category
The principles are universal; the risks are not
Qualification logic is the same across material types. What differs is where the risk actually sits, and therefore where testing and oversight should concentrate.
Active pharmaceutical ingredients
Incorrect identity, potency variability, genotoxic impurities, nitrosamines, residual solvents, polymorphic change, and microbial or endotoxin contamination. Small shifts in crystal form or impurity profile can alter dissolution, bioavailability and clinical performance.
Excipients
Often treated as low-risk because they carry no therapeutic activity. Functional variability, moisture, particle size and supplier process change can cause tablet capping, dissolution failure and content uniformity problems. Qualification confirms functional performance, not only pharmacopoeial compliance.
Botanical ingredients
Composition varies naturally with origin, climate, soil, harvest timing and processing. Species substitution, deliberate adulteration, heavy metals, pesticide residues and mycotoxins are recurring risks — often requiring chromatographic fingerprinting and botanical authentication.
Food supplement ingredients
Rapid demand growth has brought heightened scrutiny. Adulteration, heavy metals, microbial contamination, mislabelled potency and economically motivated fraud carry both consumer safety and enforcement consequences.
Framework
Qualification that concentrates effort where the risk is
Applying identical controls to every material wastes effort on low-risk inputs and under-protects high-risk ones. A risk-based framework scores materials and directs oversight accordingly.
Supplier qualification
Who manufactures the material, where, under what quality system, and with what inspection history. Supplier audits remain the strongest tool available for answering these questions properly.
Material specifications
Identity, assay, purity, impurities, particle size, moisture, residual solvents, microbial limits, packaging and storage — scientifically justified rather than inherited.
Risk assessment
Material criticality, supplier reliability, route of administration, patient population and historical performance, scored so that resources go where patient risk is greatest.
Analytical verification
Incoming confirmation of identity, purity, potency, contaminants and functional characteristics — with independent verification rather than reliance on supplier documentation for higher-risk materials.
Change control
Supplier notifications assessed for regulatory impact before implementation, not discovered afterwards during an investigation.
Periodic requalification
Confirmation that supplier performance remains consistent over time, rather than assessed once at approval and assumed thereafter.
The frameworks this sits within
| Framework | Scope | Relevance to raw materials |
|---|---|---|
| ICH Q7 | GMP for APIs | Manufacture and control expectations for active pharmaceutical ingredients. |
| ICH Q9(R1) | Quality risk management | Systematic assessment, control, communication and review of quality risk across the lifecycle. |
| ICH Q10 | Pharmaceutical quality system | The management system within which supplier oversight and change control operate. |
| ICH Q11 | Drug substance development | Development and manufacture of drug substances, including starting material justification. |
| 21 CFR 210 / 211 | US cGMP | Current good manufacturing practice for finished pharmaceuticals. |
| EudraLex Volume 4 | EU GMP | EU good manufacturing practice, alongside WHO GMP and PIC/S expectations. |
Lifecycle
Qualification does not end at supplier approval
Risk management is continuous. A supplier qualified three years ago against a process that has since changed is not a qualified supplier.
Ongoing monitoring should cover supplier performance trends and deviations, out-of-specification results and complaints, regulatory inspection findings and recalls, and change notifications and audit outcomes.
Leading organisations are moving from reactive quality systems towards predictive ones — using supplier performance data and trend analysis to identify emerging risk before it becomes a deviation. That shift depends on the qualification data being structured and available in the first place.
What we do
How we work on raw material compliance
Qualification programme design
Building or rebuilding a risk-based qualification framework, with scoring criteria that reflect your portfolio rather than a generic template.
Supplier risk assessment
Assessment of the supplier base against material criticality and quality system maturity, identifying where oversight is disproportionate to risk in either direction.
Specification review
Review and justification of material specifications, including functional requirements that pharmacopoeial compliance alone does not cover.
Impurity and contaminant strategy
Risk assessment for nitrosamines, elemental impurities, residual solvents and contaminants relevant to the material category and route of administration.
Change impact assessment
Evaluation of supplier change notifications for regulatory and quality impact, and the filings that follow from them.
Inspection readiness
Preparation of the qualification documentation an inspector will ask for, and identification of the gaps they would find first.
Bring us the challenge
Where are you in this, right now?
The most useful conversations start with the specific decision or deadline in front of you, not with a service category.